alantolactone has been researched along with Cancer of Esophagus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, L; Chen, J; Chen, T; Huang, R; Jin, J; Lian, M; Luo, L; Tang, C; Tian, R; Wang, Z; Xiang, X; Yan, L; Yu, C; Yu, L; Zhang, Y | 1 |
| Chen, H; Deng, M; He, M; Hu, Q; Li, T; Liu, H; Lü, M; Luo, G; Shi, L; Wang, Z | 1 |
2 other study(ies) available for alantolactone and Cancer of Esophagus
| Article | Year |
|---|---|
Alantolactone inhibits oesophageal adenocarcinoma cells through nuclear factor erythroid 2-related factor 2-mediated reactive oxygen species increment.
Topics: Adenocarcinoma; Animals; Apoptosis; Cell Line, Tumor; Esophageal Neoplasms; Humans; Lactones; Mice; Mice, Nude; NF-E2-Related Factor 2; Reactive Oxygen Species; Sesquiterpenes, Eudesmane | 2023 |
Inhibition of Growth of Esophageal Cancer by Alantolactone via Wnt/β- Catenin Signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Proliferation; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Female; Humans; Lactones; Mice; Mice, Inbred BALB C; Molecular Structure; Neoplasms, Experimental; Sesquiterpenes, Eudesmane; Tumor Cells, Cultured; Wnt Signaling Pathway | 2021 |